Wegovy-maker Novo Nordisk shares surge after GLP-1 pill approval
Shares in Novo Nordisk surged 6% Monday, after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly. The pill’s starting dose Continue Reading
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a Continue Reading
How donors, access and polls led Trump to reclassify marijuana
President Donald Trump’s move Thursday to sign an executive order easing federal restrictions on marijuana — and clearing the way for a Medicare pilot program covering CBD — caps a coordinated, yearlong push by the cannabis industry that combined traditional lobbying, sizable political donations, data-driven messaging and direct outreach to Continue Reading
UnitedHealth Group releases results of independent audit
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in Continue Reading
Trump reclassifies cannabis to Schedule III, easing weed restrictions
U.S. President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, D.C., U.S., Dec. 18, 2025. Evelyn Hockstein | Reuters President Donald Trump signed an executive order Thursday directing federal agencies to reclassify marijuana, loosening long-standing restrictions on the drug and marking Continue Reading
Eli Lilly obesity pill maintains weight loss after Wegovy, Zepbound
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial. The company also said it has filed for Food and Drug Continue Reading
Medline debuts on Nasdaq after biggest IPO of 2025
U.S. medical supplies giant Medline is set to debut on the Nasdaq on Wednesday after the biggest initial public offering of the year. The private equity-owned company priced at $29 per share on Tuesday, raising $6.26 billion in an upsized offering that finishes off a strong year for new listings Continue Reading
Obesity pills from Novo Nordisk, Eli Lilly are coming
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever. 2026 is likely the year that Continue Reading
Pfizer 2026 guidance shows Metsera, Seagen deals will take time to pay off
Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Continue Reading
Trump confirms potential drug reclassification, but stocks slide
Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on U.S. President Joe Biden “to take action on cannabis clemency before the November general election” October 24, 2022 in Washington, DC. Win Mcnamee | Getty Images Pot stocks failed to light up for a second Continue Reading